Clinical diagnostic criteria for dementia associated with Parkinson's disease

Abstract

Dementia has been increasingly more recognized to be a common feature in patients with Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of dementia associated with PD (PD‐D), however, have been lacking. A Task Force, organized by the Movement Disorder Study, was charged with the development of clinical diagnostic criteria for PD‐D. The Task Force members were assigned to sub‐committees and performed a systematic review of the literature, based on pre‐defined selection criteria, in order to identify the epidemiological, clinical, auxillary, and pathological features of PD‐D. Clinical diagnostic criteria were then developed based on these findings and group consensus. The incidence of dementia in PD is increased up to six times, point‐prevelance is close to 30%, older age and akinetic‐rigid form are associated with higher risk. PD‐D is characterized by impairment in attention, memory, executive and visuo‐spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent. There are no specific ancillary investigations for the diagnosis; the main pathological correlate is Lewy body‐type degeneration in cerebral cortex and limbic structures. Based on the characteristic features associated with this condition, clinical diagnostic criteria for probable and possible PD‐D are proposed. © 2007 Movement Disorder Society

Metabolic syndrome and dementia associated with Parkinson's disease: impact of age and hypertension

“…The data available showed that the mean prevalence of dementia associated with PD was 30%, with a range from 4% to 93% 1,15 . This large variability can be explained by the different methodologies used in different studies.…”

Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate

“…All patients fulfilled current consensus criteria for the relevant diagnosis (Armstrong et al, 2013; Emre et al, 2007; Hoglinger et al, 2017); none presented with speech or language disturbance as the leading clinical feature. In addition, all had a history of cognitive symptoms significant enough to interfere with everyday functioning with previous documentation of objective cognitive impairment on clinical neuropsychometry.…”

Disrupted identities: movement, mind, and memory in Parkinson's disease

“…The field took a significant step forward with two further landmark papers, namely the publication of the clinical diagnostic criteria for dementia associated with Parkinson's disease ("PDD"; Emre et al, 2007) and the successful EXPRESS (Exelon in Parkinson's Disease Dementia Study) trial of rivastigmine in PDD (Emre et al, 2004). The latter paved the way for the first (and to date, only) clinically licensed medication for treatment of the clinical symptoms of PDD.…”